ArticleEClinicalMedicine2025

First-line camrelizumab plus pemetrexed and carboplatin for advanced non-squamous non-small-cell lung cancer with brain metastases (CAP-BRAIN): final results of a multicentre, open-label, single-arm, phase 2 trial in China.

Xue Hou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.